Shaily Engineering Plastics Ltd

- The company plans to fund the new Abu Dhabi facility through a mix of internal accruals and debt. - They will be approaching bankers both in India and Abu Dhabi for funding the expansion. - No explicit mention of new equity fundraising in the provided excerpts. - For other expansions (e.g., consumer electronics business), capex plans are being worked on but no specific fundraising details provided yet. - Existing and upcoming contracts are backed by take-or-pay agreements ensuring firm commitments, reducing funding risk.

- Expansion in India: Adding 25 million pen capacity with two new lines, one under qualification (arrived Dec), the second arriving end April/beginning May, targeting total capacity of 80 million pens by FY '28. - UAE (Abu Dhabi) Facility: 18-20 months lead time for setup; funding through mix of internal accruals, debt, and support from Abu Dhabi bankers. Around 50-60% capacity commitments secured. Facility will provide business continuity and cater to large volume contracts; potential further expansion if 50 million additional pens commitment arises. - Consumer Electronics Business: Capex plans for this new segment are being worked on, with no concrete details yet. - Overall expansions are largely backed by commercial contracts and take-or-pay agreements to mitigate risks.

- Healthcare segment revenue grew 158% Y-o-Y for 9 months FY '26, indicating high growth potential. - Consumer segment revenue declined slightly (-1%) but expected to rebound as global economies improve and trade agreements finalize. - Current pen volume guidance for FY '26 is ~30 million, with expected gradual scale-up; UAE expansion planned to support higher volumes by FY '28. - Innovator contracts could add 50-100 million pen volumes over the next few years, but timelines uncertain (launch 2-3 years post agreement). - UK subsidiary has 7 new projects in pipeline, expected to deliver strong growth over 3-4 years. - Consumer electronics segment expected to scale over next 12-18 months with high-margin, complex parts. - Capacity utilization projected around 70-80% by FY '28 with UAE expansion. - Overall, long-term growth driven by healthcare (GLP-1 drugs), innovator partnerships, and expanding international markets.

- Strong revenue growth driven by healthcare segment: 158% growth YoY in 9 months FY '26; consumer segment stable with slight decline. - Expansion in pen injector capacity from 30 million to 80 million pens by FY '28, supporting volume growth. - Innovator contracts expected to add significant volumes (50-100 million pens), but likely post-2028. - New consumer electronics segment targeted for high-complexity, high-margin parts; scalable long-term growth opportunity. - EBITDA margins improved by 720 bps YoY to 29% in 9 months FY '26; PAT margins increased by 590 bps to 17.2%. - Price erosion anticipated to stabilize after initial 24 months despite competitive pressures. - UAE expansion planned by end FY '28 to support large-volume contracts and diversify operations. - Overall, management remains bullish on strong earnings growth with improving margins and capacity-driven scale-up over next 2-3 years.

- The capacity expansion in India (totaling around 80 million pens) is more or less fully backed by commercial contracts. - The Abu Dhabi expansion capacity is around 50% to 60% secured through capacity commitments. - The company anticipates being fully backed by contracts for Abu Dhabi facility approximately 18 months out. - For the innovator business, a potential of 50 to 100 million pens is seen, but exact timelines (2029-2031) are uncertain. - Take-or-pay contracts are in place, ensuring minimum volume commitments from customers. - The company has ongoing advanced stage discussions, with potential new contracts for innovative GLP-1 molecules possibly signing in the current year. - GLP-1 injector supplies have already started for launches in Canada, Brazil, India, Middle East, and Turkey. - Overall, the order book is solid and supports ongoing and upcoming capacity expansions.